Advertisement
Screener

INTEGRATED BIOPHARMA INC (INBP) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2.0 / 5 stars · 47/116 Roast Me

INTEGRATED BIOPHARMA INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

INTEGRATED BIOPHARMA INC (INBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 526.50 thousand shares for the 9-month period ending 2026-03-31, per its 10-Q filed 2026-05-08.

Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-05-08

  • INTEGRATED BIOPHARMA INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares.
  • INTEGRATED BIOPHARMA INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 200.00K shares.
  • INTEGRATED BIOPHARMA INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 0.00 shares.
  • INTEGRATED BIOPHARMA INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 490.00K shares, a 15.88% decline year-over-year.
  • INTEGRATED BIOPHARMA INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 890.00K shares, a 13.74% increase from fiscal 2024.
  • INTEGRATED BIOPHARMA INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 782.50K shares, a 48.48% increase from fiscal 2023.
  • INTEGRATED BIOPHARMA INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 527.00K shares, a 31.08% decline from fiscal 2022.
  • INTEGRATED BIOPHARMA INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 764.70K shares, a 0.69% decline from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month
2026-03-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-08
526.50K shares
10-Q · filed 2026-05-08
2025-12-31526.50K shares
10-Q · filed 2026-02-11
2025-06-30200.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23
200.00K shares
derived: sum of 2 quarters · filed 2025-09-23
690.00K shares
derived: sum of 3 quarters · filed 2025-09-23
890.00K shares
10-K · filed 2025-09-23
2025-03-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14
490.00K shares
derived: sum of 2 quarters · filed 2025-05-14
690.00K shares
10-Q · filed 2025-05-14
690.00K shares
derived: sum of 4 quarters · filed 2025-09-23
2024-12-31490.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-13
690.00K shares
10-Q · filed 2025-02-13
690.00K shares
derived: sum of 3 quarters · filed 2025-09-23
690.00K shares
derived: sum of 4 quarters · filed 2025-09-23
2024-09-30200.00K shares
10-Q · filed 2024-11-13
200.00K shares
derived: sum of 2 quarters · filed 2025-09-23
200.00K shares
derived: sum of 3 quarters · filed 2025-09-23
782.50K shares
derived: sum of 4 quarters · filed 2025-09-23
2024-06-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23
0.00 shares
derived: sum of 2 quarters · filed 2025-09-23
582.50K shares
derived: sum of 3 quarters · filed 2025-09-23
782.50K shares
10-K · filed 2025-09-23
2024-03-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-10
582.50K shares
derived: sum of 2 quarters · filed 2024-05-10
782.50K shares
10-Q · filed 2024-05-10
782.50K shares
derived: sum of 4 quarters · filed 2024-09-20
2023-12-31582.50K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-12
782.50K shares
10-Q · filed 2024-02-12
782.50K shares
derived: sum of 3 quarters · filed 2024-09-20
782.50K shares
derived: sum of 4 quarters · filed 2024-09-20
2023-09-30200.00K shares
10-Q · filed 2023-11-09
200.00K shares
derived: sum of 2 quarters · filed 2024-09-20
200.00K shares
derived: sum of 3 quarters · filed 2024-09-20
2023-06-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-20
0.00 shares
derived: sum of 2 quarters · filed 2024-09-20
527.00K shares
10-K · filed 2024-09-20
2023-03-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11
527.00K shares
10-Q · filed 2023-05-11
2022-12-31527.00K shares
10-Q · filed 2023-02-10
2022-06-30200.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-15
200.00K shares
derived: sum of 2 quarters · filed 2023-09-15
764.70K shares
10-K · filed 2023-09-15
2022-03-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-12
564.70K shares
10-Q · filed 2022-05-12
2021-12-31564.70K shares
10-Q · filed 2022-02-10
2021-06-30770.00K shares
10-K · filed 2022-09-13
2019-06-301.88M shares
10-K · filed 2020-09-23
2017-06-30200.00K shares
10-K · filed 2018-09-12
2016-06-300.00 shares
10-K · filed 2016-09-02
2015-06-302.25M shares
10-K · filed 2016-09-02
2.25M shares
10-K · filed 2016-09-02
2014-06-30-25.00K shares
10-K · filed 2014-09-08
2013-06-300.00 shares
10-K · filed 2013-09-30
2012-06-300.00 shares
10-K · filed 2013-09-30
2011-06-300.00 shares
10-K · filed 2012-10-15